Research Article
Meta-Analysis of miRNA Variants Associated with Susceptibility to Autoimmune Disease
Table 1
The general characteristics of all studies included in our meta-analysis.
| | Refs | Year | Disease | Group | Mean age | Female (%) | Country | Ethnicity | Case/control | Typing method | NOS score | MAF control | HWE control |
| | Srivastava et al. [78] | 2017 | GD | AITD | 36.92 | 69.5 | China | East Asian | 678/918 | LDR | 6 | 0.42 | Yes | | Srivastava et al. [78] | 2017 | HD | AITD | 35.03 | 87.8 | China | East Asian | 344/918 | LDR | 6 | 0.42 | Yes | | Wang and Pan [25] | 2015 | AS | Arthritis | 34.88 | 25.9 | China | East Asian | 102/105 | Sequence | 7 | 0.35 | Yes | | Zhang et al. [8] | 2015 | AS | Arthritis | — | 21.3 | China | East Asian | 609/616 | Sequence | 6 | 0.41 | Yes | | Gazouli et al. [54] | 2017 | Asthma | Asthma | 6.20 | 52.3 | China | East Asian | 124/206 | TaqMan | 7 | 0.36 | Yes | | Higgins et al. [30] | 2011 | Asthma | Asthma | 35.4 | 52.9 | China | East Asian | 219/513 | RFLP | 8 | 0.45 | Yes | | Zha et al. [44] | 2017 | Asthma | Asthma | 41.8 | 58.5 | Korea | East Asian | 341/170 | SNaPShot | 6 | 0.38 | Yes | | Fenoglio et al. [6] | 2012 | Asthma | Asthma | 8.40 | 41.0 | Mexico | Hispanic | 402/531 | TaqMan | 7 | 0.34 | Yes | | Fenoglio et al. [6] | 2012 | SLE | SLE | 11.61 | 83.0 | Mexico | Hispanic | 367/531 | TaqMan | 7 | 0.34 | Yes | | Fenoglio et al. [6] | 2012 | JRA/JIA | Arthritis | 8.70 | 59.0 | Mexico | Hispanic | 210/531 | TaqMan | 7 | 0.34 | Yes | | El-Shal et al. [43] | 2015 | BD | Uveitis | 34.8 | 50.0 | Turkey | Middle East | 100/145 | RFLP | 6 | 0.33 | NO | | Senousy et al. [12] | 2020 | BD | Uveitis | 33.4 | 51.3 | Turkey | Middle East | 117/220 | RFLP | 7 | 0.32 | Yes | | Ghobadi et al. [68] | 2014 | BD | Uveitis | 32.1 | 16.2 | China | East Asian | 809/1132 | RFLP | 9 | 0.36 | Yes | | Ghobadi et al. [68] | 2014 | VKH | Uveitis | 33.2 | 46.8 | China | East Asian | 613/1132 | RFLP | 9 | 0.36 | Yes | | Ahmed et al. [94] | 2018 | BD | Uveitis | 34.4 | 14.9 | Egypt | Middle East | 47/50 | TaqMan | 6 | 0.44 | Yes | | Abdelaleem et al. [46] | 2013 | CD | IBD | 51.3 | 55.4 | Greece | Caucasian | 242/300 | RFLP | 7 | 0.18 | Yes | | Abdelaleem et al. [46] | 2013 | UC | IBD | 50.9 | 51.9 | Greece | Caucasian | 210/300 | RFLP | 7 | 0.18 | Yes | | Zhou et al. [77] | 2017 | CD | IBD | 30.0 | 51.3 | Italy | Caucasian | 244/298 | TaqMan | 6 | 0.27 | Yes | | Zhou et al. [77] | 2017 | UC | IBD | 37.4 | 41.1 | Italy | Caucasian | 206/298 | TaqMan | 6 | 0.27 | Yes | | Dong et al. [27] | 2016 | CD | IBD | 43.8 | 48.0 | China | East Asian | 227/450 | RFLP | 7 | 0.44 | Yes | | Dong et al. [27] | 2016 | UC | IBD | 41.7 | 46.9 | China | East Asian | 241/450 | RFLP | 7 | 0.44 | Yes | | Zhu et al. [36] | 2014 | IgA | IgA | 11.8 | 41.8 | China | East Asian | 404/711 | LDR | 8 | 0.44 | Yes | | Aleman-Avila et al. [61] | 2015 | IgA | IgA | 33.5 | 52.0 | China | East Asian | 145/179 | Roche | 7 | 0.34 | Yes | | Che et al. [33] | 2014 | JRA/JIA | Arthritis | 11.0 | 11.3 | India | East Asian | 150/216 | RFLP | 6 | 0.27 | Yes | | Fattah et al. [93] | 2018 | KD | KD | 28.4 | 31.4 | China | East Asian | 532/616 | TaqMan | 9 | 0.39 | Yes | | Yang et al. [35] | 2019 | KD | KD | — | 33.3 | China | East Asian | 120/126 | RFLP | 6 | 0.40 | Yes | | Atkins et al. [29] | 2019 | MS | Sclerosis | 31.3 | 84.2 | Egypt | Middle East | 76/120 | TaqMan | 6 | 0.45 | Yes | | Atkins et al. [29] | 2019 | SLE | SLE | 32.3 | 90.0 | Egypt | Middle East | 80/120 | TaqMan | 6 | 0.45 | Yes | | Hu and Daly [4] | 2011 | MS | Sclerosis | 46.3 | 69.4 | Italy | Caucasian | 346/339 | TaqMan | 7 | 0.26 | NO | | Inoue et al. [57] | 2015 | MS | Sclerosis | 32.6 | 72.8 | China | East Asian | 525/568 | SNaPShot | 7 | 0.44 | Yes | | Yu et al. [92] | 2019 | MS | Sclerosis | 27.4 | 66.1 | Russia | Caucasian | 109/424 | TaqMan | 8 | 0.22 | Yes | | Wang et al. [10] | 2020 | Osteoarthritis | Arthritis | 66.6 | 79.4 | Greece | Caucasian | 950/738 | RFLP | 6 | 0.22 | Yes | | Zhou et al. [73] | 2014 | Polymyositis | Polymyositis | 58.7 | 60.9 | Japan | East Asian | 44/107 | RFLP | 3 | 0.28 | NO | | Vreca et al. [71] | 2018 | PsA | Arthritis | 50.3 | 46.0 | Caucasian | Caucasian | 38/32 | RFLP | 6 | 0.36 | Yes | | Vreca et al. [71] | 2018 | PsA | Arthritis | 50.3 | 46.0 | Indian | East Asian | 62/84 | RFLP | 6 | 0.36 | Yes | | Ciccacci et al. [86] | 2020 | Psoriasis | Psoriasis | — | — | Italy | Caucasian | 393/600 | TaqMan | 7 | 0.30 | Yes | | Ciccacci et al. [86] | 2020 | PsA | Arthritis | — | — | Italy | Caucasian | 424/600 | TaqMan | 7 | 0.30 | Yes | | Desai and Brinton [3] | 2010 | PsA | Arthritis | 48.5 | 34.5 | Greece | Caucasian | 29/66 | RFLP | 6 | 0.27 | NO | | Jimeneze-Morales et al. [7] | 2014 | Psoriasis | Psoriasis | 32.1 | 45.3 | China | East Asian | 521/582 | RFLP | 7 | 0.42 | Yes | | Golshani et al. [69] | 2016 | Psoriasis | Psoriasis | — | 49.0 | Sweden | Caucasian | 1546/1526 | TaqMan | 6 | 0.21 | Yes | | Nottrott et al. [22] | 2019 | Psoriasis | Psoriasis | 49.7 | — | Czech | Caucasian | 241/516 | RFLP | 8 | 0.22 | Yes | | Zhang et al. [72] | 2013 | SS | Sclerosis | — | — | Japan | East Asian | 107/52 | RFLP | 1 | 0.29 | NO | | Luo et al. [62] | 2018 | SS | Sclerosis | 57.7 | 86.3 | Serbia | Caucasian | 102/66 | Sequence | 6 | 0.17 | Yes | | Ayeldeen et al. [90] | 2016 | T1DM | T1DM | 43.6 | 48.5 | Australia | Oceanian | 419/823 | MALDI-TOF | 6 | 0.23 | Yes | | Wei et al. [76] | 2017 | T1DM | T1DM | 34.3 | 49.7 | Brazil | Hispanic | 431/405 | TaqMan | 7 | 0.33 | Yes | | Leng et al. [65] | 2012 | Fuchs | Uveitis | 36.4 | 46.6 | China | East Asian | 219/612 | RFLP | 9 | 0.36 | Yes | | Lofgren et al. [67] | 2014 | PU | Uveitis | 9.60 | 53.5 | China | East Asian | 520/1204 | RFLP | 9 | 0.37 | Yes | | Lin et al. [45] | 2011 | UC | IBD | 40.2 | 43.5 | Japan | East Asian | 170/403 | RFLP | 8 | 0.40 | Yes | | Takuse et al. [41] | 2011 | SLE | SLE | 34.5 | 94.4 | China | East Asian | 213/209 | RFLP | 7 | 0.36 | Yes | | Trinh et al. [52] | 2017 | SLE | SLE | 39.9 | 94.3 | Mexico | Hispanic | 407/486 | TaqMan | 8 | 0.32 | Yes | | Trinh et al. [52] | 2017 | RA | Arthritis | 51.8 | 91.7 | Mexico | Hispanic | 410/486 | TaqMan | 8 | 0.32 | Yes | | Trinh et al. [52] | 2017 | GD | AITD | 36.2 | 88.9 | Mexico | Hispanic | 81/486 | TaqMan | 8 | 0.32 | Yes | | Wang et al. [58] | 2012 | SLE | SLE | — | — | Sweden | Caucasian | 1109/1428 | TaqMan | 7 | 0.24 | Yes | | Hassine et al. [75] | 2010 | RA | Arthritis | 60.8 | 80.0 | Greece | Caucasian | 136/147 | RFLP | 6 | 0.28 | Yes | | Sheng et al. [34] | 2013 | RA | Arthritis | 38.4 | — | Egypt | Middle East | 217/245 | RFLP | 7 | 0.30 | NO | | Su et al. [39] | 2018 | RA | Arthritis | 39.5 | 84.6 | Egypt | Middle East | 104/112 | TaqMan | 9 | 0.32 | Yes | | Singh et al. [42] | 2013 | RA | Arthritis | 38.4 | 46.9 | Iran | Middle East | 104/110 | RFLP | 7 | 0.25 | Yes | | Burmester and Pope [5] | 2011 | RA | Arthritis | 48.0 | 41.7 | China | East Asian | 208/240 | RFLP | 6 | 0.37 | Yes | | Qi et al. [64] | 2015 | RA | Arthritis | 54.5 | 76.7 | China | East Asian | 598/821 | SNPscan | 9 | 0.42 | Yes | | Li et al. [66] | 2017 | RA | Arthritis | — | 91.0 | Tunisian | Middle East | 165/150 | MS-PCR | 8 | 0.32 | Yes | | Li et al. [40] | 2019 | RA | Arthritis | 39.0 | 81.7 | China | East Asian | 126/102 | Roche | 6 | 0.33 | Yes | | Ibrahim et al. [79] | 2016 | RA | Arthritis | 54.1 | 76.5 | Italy | Caucasian | 192/298 | TaqMan | 7 | 0.27 | Yes | | Sakoguchi et al. [81] | 2018 | RA | Arthritis | 39.5 | 84.6 | Egypt | Middle East | 52/56 | TaqMan | 8 | 0.32 | Yes | | Cai et al. [87] | 2017 | RA | Arthritis | — | — | Poland | Caucasian | 111/130 | RFLP | 6 | 0.18 | Yes | | Maharaj et al. [80] | 2020 | RA | Arthritis | 48.2 | 73.0 | Iran | Middle East | 89/237 | T-ARMS-PCR | 8 | 0.32 | Yes | | Maharaj et al. [80] | 2020 | SLE | SLE | 45.2 | 92.0 | Iran | Middle East | 50/237 | T-ARMS-PCR | 8 | 0.32 | Yes | | Chen et al. [24] | 2015 | SLE | SLE | 34.0 | 93.9 | China | East Asian | 1047/1205 | MALDI-TOF | 7 | 0.18 | Yes | | Chen et al. [24] | 2015 | SLE | SLE | 34.7 | 91.5 | China | East Asian | 2202/2208 | MALDI-TOF | 7 | 0.17 | Yes | | Chen et al. [24] | 2015 | SLE | SLE | 33.1 | 93.3 | China | East Asian | 1307/6038 | MALDI-TOF | 7 | 0.17 | Yes | | Humphreys et al. [21] | 2015 | SLE | SLE | 36.0 | 89.4 | China | East Asian | 322/353 | RFLP | 7 | 0.19 | Yes | | Assmann et al. [85] | 2020 | MS | Sclerosis | 31.3 | 84.2 | Egypt | Middle East | 114/152 | TaqMan | 6 | 0.34 | Yes | | Okubo et al. [53] | 2011 | SLE | SLE | — | — | China | East Asian | 2352/1080 | Sequence | 6 | 0.16 | Yes | | Okubo et al. [53] | 2011 | SLE | SLE | — | — | China | East Asian | 1152/1152 | TaqMan | 6 | 0.20 | Yes | | Okubo et al. [53] | 2011 | SLE | SLE | — | — | Thailand | East Asian | 464/982 | TaqMan | 6 | 0.23 | Yes | | Yang et al. [56] | 2012 | SLE | SLE | 35.8 | 89.7 | China | East Asian | 858/967 | MALDI-TOF | 7 | 0.20 | Yes | | Ranjha et al. [47] | 2018 | BD | Uveitis | — | — | Iran | Middle East | 100/100 | T-ARMS-PCR | 8 | 0.19 | Yes | | Shaker et al. [37] | 2020 | BD | Uveitis | 33.6 | 13.1 | Egypt | Middle East | 130/131 | TaqMan | 7 | 0.32 | Yes | | Hu et al. [49] | 2020 | AS | Arthritis | 28.4 | 29.0 | China | East Asian | 200/200 | RFLP | 6 | 0.47 | Yes | | Zare-Karizi et al. [55] | 2013 | BD | Uveitis | 33.5 | 13.6 | China | East Asian | 859/1685 | RFLP | 9 | 0.45 | Yes | | Zare-Karizi et al. [55] | 2013 | VKH | Uveitis | 35.5 | 44.5 | China | East Asian | 400/400 | RFLP | 9 | 0.48 | Yes | | Zare-Karizi et al. [55] | 2013 | AAU+as+ | Uveitis | 39.5 | 24.9 | China | East Asian | 209/400 | RFLP | 9 | 0.48 | Yes | | Zhou et al. [74] | 2016 | Asthma | Asthma | 9.70 | 45.8 | Egypt | Middle East | 96/96 | TaqMan | 7 | 0.30 | Yes | | Niu et al. [9] | 2019 | KD | KD | 28.4 | 31.4 | China | East Asian | 531/623 | TaqMan | 6 | 0.47 | Yes | | Yu et al. [60] | 2018 | MS | Sclerosis | 30.0 | 75.0 | Iran | Middle East | 80/80 | T-ARMS-PCR | 7 | 0.34 | Yes | | Yang et al. [70] | 2019 | T1DM | T1DM | 13.0 | 58.0 | Egypt | Middle East | 150/150 | T-ARMS-PCR | 7 | 0.31 | Yes | | Labib et al. [38] | 2017 | UC | IBD | 35.5 | 40.6 | India | East Asian | 197/441 | RFLP | 6 | 0.22 | Yes | | Ridolfi et al. [59] | 2017 | UC | IBD | 35.9 | 60.0 | Iran | Middle East | 210/212 | RFLP | 7 | 0.39 | Yes | | Okada et al. [82] | 2016 | RA | Arthritis | 46.1 | 88.4 | Egypt | Middle East | 95/200 | TaqMan | 6 | 0.28 | Yes | | Ahmadi et al. [89] | 2016 | Asthma | Asthma | 44.9 | 39.8 | China | East Asian | 591/621 | MALDI-TOF | 8 | 0.11 | Yes | | Toraih et al. [91] | 2017 | Asthma | Asthma | 9.7 | 45.8 | Egypt | Middle East | 211/330 | TaqMan | 7 | 0.35 | Yes | | Li et al. [26] | 2017 | RA | Arthritis | 51.9 | 86.0 | China | East Asian | 386/576 | TaqMan | 6 | 0.12 | Yes | | Hu et al. [63] | 2013 | RA | Arthritis | 54.6 | 71.5 | China | East Asian | 206/466 | MALDI-TOF | 8 | 0.14 | Yes | | Chatzikyriakidou et al. [84] | 2018 | RA | Arthritis | 41.7 | 86.0 | Egypt | Middle East | 100/100 | RFLP | 7 | 0.31 | Yes | | Tang et al. [31] | 2019 | KD | KD | 28.4 | 31.4 | China | East Asian | 507/612 | TaqMan | 6 | 0.19 | Yes | | Ciccacci et al. [88] | 2015 | RA | Arthritis | 49.0 | — | China | East Asian | 186/120 | RFLP | 8 | 0.28 | Yes | | Hruska et al. [32] | 2017 | GD | AITD | — | — | Japan | East Asian | 118/76 | RFLP | 7 | 0.36 | Yes | | Hruska et al. [32] | 2017 | HD | AITD | — | — | Japan | East Asian | 141/76 | RFLP | 7 | 0.36 | Yes | | Oner et al. [51] | 2014 | AAU + AS+ | Uveitis | 39.3 | 34.0 | China | East Asian | 230/650 | RFLP | 9 | 0.08 | Yes | | Oner et al. [51] | 2014 | AAU + AS- | Uveitis | 39.3 | 34.0 | China | East Asian | 240/650 | RFLP | 9 | 0.08 | Yes | | Hussein et al. [83] | 2014 | BD | Uveitis | 33.6 | 14.2 | China | East Asian | 400/600 | RFLP | 9 | 0.07 | Yes | | Hussein et al. [83] | 2014 | VKH | Uveitis | 39.3 | 47.6 | China | East Asian | 900/1800 | RFLP | 9 | 0.07 | Yes | | Shaker et al. [48] | 2014 | GD | AITD | 34.5 | 84.8 | Japan | East Asian | 155/118 | RFLP | 7 | 0.13 | Yes | | Shaker et al. [48] | 2014 | HD | AITD | 37.1 | 82.0 | Japan | East Asian | 151/118 | RFLP | 7 | 0.13 | Yes | | Zhang et al. [50] | 2013 | MS | Sclerosis | 40.3 | 73.3 | Italy | Caucasian | 399/420 | TaqMan | 8 | 0.24 | Yes | | Petersen et al. [23] | 2018 | KD | KD | 28.4 | 31.4 | China | East Asian | 527/622 | TaqMan | 7 | 0.06 | Yes | | Papathanasiou et al. [11] | 2020 | MS | Sclerosis | 31.2 | 77.8 | Egypt | Middle East | 108/104 | TaqMan | 6 | 0.35 | Yes | | Caputo et al. [95] | 2020 | SLE | SLE | 31.8 | 93.8 | Egypt | Middle East | 65/40 | TaqMan | 8 | 0.43 | Yes | | Chatzikyriakidou et al. [96] | 2020 | T1DM | T1DM | 42.1 | 50.3 | Brazil | Hispanic | 195/215 | TaqMan | 8 | 0.27 | Yes | | Bogunia-Kubik et al. [97] | 2020 | CD | IBD | 36.0 | 56 | America | Caucasian | 19/23 | TaqMan | 6 | 0.22 | Yes |
|
|
GD: Graves’ disease; AITD: autoimmune thyroid disease; HD: Hashimoto’s disease; AS: ankylosing spondylitis; SLE: systemic lupus erythematosus; JRA/JIA: juvenile idiopathic/rheumatoid arthritis; BD: Behcet’s disease; VKH: Vogt-Koyanagi-Harada; CD: Crohn’s disease; UC: ulcerative colitis; IBD: inflammatory bowel disease; IgA : IgA nephropathy; KD: Kawasaki disease; MS: multiple sclerosis; PsA: psoriatic arthritis; SS: systemic sclerosis; T1DM: type 1 diabetes mellitus; PU: pediatric uveitis; RA: rheumatoid arthritis; AAU +AS +: acute anterior uveitis with ankylosing spondylitis; AAU +AS +: acute anterior uveitis without ankylosing spondylitis; LDR: ligase detection reaction; RFLP: restriction fragment length polymorphism; MALDI-TOF: matrix-assisted laser desorption ionization-time of flight; MS-PCR: methylation-specific polymerase chain reaction; T-ARMS-PCR: tetra amplification refractory mutation system-polymerase chain reaction; MAF: minimal allele frequency; NA: not available; HWE: Hardy Weinberg equilibrium. |
